Compare Adaptive Biotechnologies Corp (ADPT) vs NIO Inc. (NIO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs NIO Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while NIO Inc. trades at $4.9 (market cap $12.57B). The key difference: NIO Inc. is far larger — about 3.8× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| ADPT | NIO | |
|---|---|---|
Market Cap | $3.33B | $12.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $7.89 |
52-Week Low | $10.24 | $3.48 |
Enterprise Value | $3.19B | $11.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
NIO trades at $4.88, up 1.88% with bearish technical signals despite strong delivery growth. The company shows improving fundamentals with revenue reaching $87.49B in 2025 and narrowing losses, though negative profitability metrics persist. Recent June deliveries surged 62.9% year-over-year, supporting margin expansion expectations. Analyst sentiment remains mixed with 50% buy ratings amid ongoing cash burn concerns.
NIO presents a high-risk turnaround opportunity with accelerating delivery growth and improving margins, but substantial losses and negative cash flow require careful monitoring. The stock faces technical resistance near $5 while benefiting from EV sector momentum and premium positioning in China's competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
